Critical Analysis of the Efficacy and Limitations of GLP-1 Pharmaceuticals in Obesity Management: A Comprehensive Literature Review
DOI:
https://doi.org/10.12775/JEHS.2024.55.006Keywords
Obesity, Diabetes, Pharmacotherapy, Prevention, GLP-1, EpidemiologyAbstract
Introduction and purpose
Obesity, a pervasive global pandemic intricately linked to various comorbidities, necessitates a comprehensive and nuanced approach. This article delves into the intricate realm of obesity guidelines, underscoring the significance of lifestyle modifications, preventive measures for childhood obesity, population-based strategies, clinical management protocols, and vigilant monitoring.
GLP-1 drugs, originally designed for type 2 diabetes management, exhibit multifaceted effects beyond glycemic control. They influence appetite regulation, gastric emptying dynamics, and potentially contribute to cardiovascular health improvements. However, the commendable effects come with a caveat - potential side effects necessitating careful consideration in clinical decision-making. Despite gaining popularity through celebrity endorsements, this article firmly underscores the need to view GLP-1 pharmacotherapy as a recommended intervention rather than a miraculous solution.
A brief description of the state of knowledge
Integral to the obesity discourse is the imperative to address weight stigma, demanding evidence-based approaches in both clinical and public health domains. The narrative extends into the future landscape of obesity pharmacotherapy, contemplating the potential role of probiotics. Emphasizing the necessity for long-term studies and randomized trials, it positions probiotics as a low-risk alternative with significant potential in mitigating obesity while simultaneously addressing concerns related to antibiotic resistance.
Summary
The pursuit of a balanced and effective approach to obesity management necessitates a nuanced understanding of medical interventions, consideration of societal perceptions, and exploration of innovative possibilities within the evolving landscape of healthcare.
References
Cuciureanu, M., Caratașu, C. C., Gabrielian, L., Frăsinariu, O. E., Checheriță, L. E., Trandafir, L. M., Stanciu, G. D., Szilagyi, A., Pogonea, I., Bordeianu, G., Soroceanu, R. P., Andrițoiu, C. V., Anghel, M. M., Munteanu, D., Cernescu, I. T., & Tamba, B. I. (2023). 360-Degree Perspectives on Obesity. Medicina (Lithuania), 59(6), 1–51. https://doi.org/10.3390/medicina59061119
Sarma, S., Tran, S., & Fralick, M. (2023). Novel obesity treatments. CMAJ: Canadian Medical Association Journal = Journal de l’Association Medicale Canadienne, 195(45), E1546–E1547. https://doi.org/10.1503/cmaj.230820
Shaefer, C. F., Kushner, P., & Aguilar, R. (2015). User’s guide to mechanism of action and clinical use of GLP-1 receptor agonists. Postgraduate Medicine, 127(8), 818–826. https://doi.org/10.1080/00325481.2015.1090295
Maselli, D. B., & Camilleri, M. (2021). Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity. Advances in Experimental Medicine and Biology, 1307, 171–192. https://doi.org/10.1007/5584_2020_496
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014). Adverse Effects of GLP-1 Receptor Agonists. The Review of Diabetic Studies : RDS, 11(3–4), 202–230. https://doi.org/10.1900/RDS.2014.11.202
Mazloom, K., Siddiqi, I., & Covasa, M. (2019). Probiotics: How effective are they in the fight against obesity? Nutrients, 11(2), 1–24. https://doi.org/10.3390/nu11020258
Rubino, F., Puhl, R. M., Cummings, D. E., Eckel, R. H., Ryan, D. H., Mechanick, J. I., Nadglowski, J., Ramos Salas, X., Schauer, P. R., Twenefour, D., Apovian, C. M., Aronne, L. J., Batterham, R. L., Berthoud, H. R., Boza, C., Busetto, L., Dicker, D., De Groot, M., Eisenberg, D., … Dixon, J. B. (2020). Joint international consensus statement for ending stigma of obesity. Nature Medicine, 26(4), 485–497. https://doi.org/10.1038/s41591-020-0803-x
Lobstein, T. (2019). Obesity prevention and the Global Syndemic: Challenges and opportunities for the World Obesity Federation. Obesity Reviews, 20(S2), 6–9. https://doi.org/10.1111/obr.12888
van Sluijs, E. M. F., Ekelund, U., Crochemore-Silva, I., Guthold, R., Ha, A., Lubans, D., Oyeyemi, A. L., Ding, D., & Katzmarzyk, P. T. (2021). Physical activity behaviours in adolescence: current evidence and opportunities for intervention. The Lancet, 398(10298), 429–442. https://doi.org/10.1016/S0140-6736(21)01259-9
Smith, K. B., & Smith, M. S. (2016). Obesity Statistics. Primary Care - Clinics in Office Practice, 43(1), 121–135. https://doi.org/10.1016/j.pop.2015.10.001
E.P. Williams, M. Mesidor, K. Winters, P.M. Dubbert, S.B. Wyatt, Overweight and obesity: prevalence, consequences, and causes of a growing public health problem, Curr. Obes. Rep. 4 (3) (2015) 363–370
H.A. Raynor, C.M. Champagne, Position of the academy of nutrition and dietetics: interventions for the treatment of overweight and obesity in adults, J. Acad. Nutr. Diet. 116 (1) (2016) 129–147
National Institute of Health, National Heart, Lung, and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Obes Res 1998;6(Suppl 2):515.
WHO Consultation on Obesity. Obesity: preventing and managing the global epidemic. Geneva, 3–5 June 1997. Geneva (Switzerland): World Health Organi- zation; 1998.
Bickham DS, Blood EA, Walls CE, et al. Characteristics of screen media use associated with higher BMI in young adolescents. Pediatrics 2013;131(935): 935–41.
Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med 2002;347:305.
WangCY,McPherson K,MarshT, et al. Healthandeconomic burdenof theprojected obesity trends in the USA and the UK. Lancet 2011;378:815–25
Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C et al (2018) Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet 392 (10160):2180–2193
Acosta A, Camilleri M, Shin A, Vazquez-Roque MI, Iturrino J, Burton D et al (2015b) Quantitative gastro- intestinal and psychological traits associated with obe- sity and response to weight-loss therapy. Gastroenterology 148(3):537–546.e4
Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E. Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials. Diabetes Res Clin Pract 2014. 103(2):269-275.
Wysham C, Blevins T, Arakaki R, Colon G, Garcia P, Atisso C, Kuhstoss D, Lakshmanan M. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized con- trolled trial (AWARD-1). Diabetes Care 2014. 37(8):2159- 2167.
Nauck M, Frid A, Hermansen K, Thomsen AB, Dur- ing M, Shah N, Tankova T, Mitha I, Matthews DR. Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. Diabetes Obes Metab 2013. 15(3):204-212.
Simsek S, de Galan BE. Cardiovascular protective prop- erties of incretin-based therapies in type 2 diabetes. Curr Opin Lipidol 2012. 23(6):540-547.
Scott LJ. Liraglutide: a review of its use in adult patients with type 2 diabetes mellitus. Drugs 2014. 74(18):2161-2174.
Swinburn B, Kraak V, Allender S, et al. for the Lancet Commission on the Global Syndemic. The global syndemic of obesity, undernutrition and climate change: the Lancet Commission report. The Lancet. 2019;393(10173):791‐846.
Vallianou, N.G.; Kounatidis, D.; Tsilingiris, D.; Panagopoulos, F.; Christodoulatos, G.S.; Evangelopoulos, A.; Karampela, I.; Dalamaga, M. The Role of Next-Generation Probiotics in Obesity and Obesity-Associated Disorders: Current Knowledge and Future Perspectives. Int. J. Mol. Sci. 2023, 24, 6755. https://doi.org/10.3390/ijms24076755
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Katarzyna Gierlach, Karolina Nowak, Karolina Nowak, Zuzanna Olejarz, Magdalena Słowik, Zuzanna Drygała, Julia Wyrwał, Zuzanna Zielińska, Maria Nieć, Martyna Krasuska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 1031
Number of citations: 0
